<DOC>
	<DOCNO>NCT00296257</DOCNO>
	<brief_summary>To compare efficacy SMP-114 ( 120 240 mg/d ) versus placebo term percentage patient meet American College Rheumatology criterion 20 % improvement RA ( ACR20 ) week 24 . The study hypothesis would demonstrate use methotrexate SMP-114 efficacious Methotrexate alone .</brief_summary>
	<brief_title>Assessment Safety , Pharmacokinetics Efficacy Combination Treatment With SMP-114</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Male female patient age least 18 year , RA minimum 6 month Has receive methotrexate treatment ( stable 8 week ) Has active disease classify ACR functional class I , II III Has previously discontinue DMARD therapy due hepatic intolerance Has receive DMARD addition methotrexate 4 week prior randomisation Is receive 2 DMARDs addition methotrexate time screening Is receive receive Gold , leflunomide biological agent include TNF/IL1 inhibitor within 8 week prior randomisation Has previously fail 2 DMARDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>